EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0JAV: Insmed INC

11 Nov 2025
LAST:

192.2

CHANGE:
 2.80		OPEN:
191.0		HIGH:
192.5		ASK:
0.0		VOLUME:
913
CHG(%):
1.48		PREV:
189.4		LOW:
187.7		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 25191.0192.5187.7192.2913
10 Nov 25191.0192.4186.9189.4430
07 Nov 25184.0186.1182.8184.3129
06 Nov 25187.0188.3184.6186.2325
05 Nov 25182.9189.3182.4185.4432
04 Nov 25185.7187.6183.4184.44.9K
03 Nov 25195.3195.3178.8183.91.9K
31 Oct 25194.5196.0187.3187.6638
30 Oct 25170.0193.3168.0193.34.3K
29 Oct 25165.0167.4164.2164.3100.3K

COMPANY PROFILE

Name:Insmed INC
About:Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Address:700 US Highway 202/206, Bridgewater, NJ, United States, 08807
Website:https://www.insmed.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:4.06 
PEG Ratio:0.15 
Price to Sales:36.15 
Price to Book:40.44 
Profit Margin:-2.65 
Operating Margin:-1.84 
Return on Assets:-0.28 
Return on Equity:-1.66 
EPS Ratio:-3.78 
Revenue:447.02M 
EBITDA:148.09B 
Shares:77.09M 
Market Cap:14.817B 

TECHNICAL INDICATORS

MA5:187.492.5%
MA10:185.093.8%
MA20:174.1610.4%
MA50:158.6921.1%
MA100:135.3742.0%
MA200:105.6282.0%
STO9:68.93
STO14:90.00 
RSI14:74.75 
WPR14:-3.01 
MTM14:33.84
ROC14:0.21 
ATR:7.63 
Week High:192.500.2%
Week Low:182.445.3%
Month High:195.962.0%
Month Low:154.8982.0%
Year High:195.962.0%
Year Low:61.28213.7%

RECENT DIVIDENDS

Date Amount
29 Sep 2022$17.00
30 Mar 2022$13.00
29 Sep 2021$13.00
30 Mar 2021$7.50
29 Sep 2020$7.50
30 Mar 2020$13.00
27 Sep 2019$13.00
27 Mar 2019$13.00
26 Sep 2018$10.00
28 Mar 2018$7.50